Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG.

J Clin Oncol. 2008 Feb 1;26(4):639-43. doi: 10.1200/JCO.2007.10.8605.

2.

Albumin-bound paclitaxel: a next-generation taxane.

Gradishar WJ.

Expert Opin Pharmacother. 2006 Jun;7(8):1041-53. Review.

PMID:
16722814
3.

ABI 007.

[No authors listed]

Drugs R D. 2004;5(3):155-9. Review.

PMID:
15139776
4.

nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.

Hirsh V.

Expert Rev Anticancer Ther. 2014 Feb;14(2):129-41. doi: 10.1586/14737140.2014.881719. Review.

PMID:
24467217
5.

First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.

Gupta N, Hatoum H, Dy GK.

Int J Nanomedicine. 2014;9:209-21. doi: 10.2147/IJN.S41770. Epub 2013 Dec 24. Review.

6.

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.

Henderson IC, Bhatia V.

Expert Rev Anticancer Ther. 2007 Jul;7(7):919-43. Review.

PMID:
17627452
7.

[S-1 combined with weekly paclitaxel in patients with advanced gastric cancer].

Gotoh M, Kawabe S, Takiuchi H.

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:91-4. Review. Japanese.

PMID:
16897980
8.

Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.

Chirgwin J, Chua SL.

Breast. 2011 Oct;20(5):394-406. doi: 10.1016/j.breast.2011.06.004. Epub 2011 Aug 11. Review.

PMID:
21839635
10.

CT-2103: emerging utility and therapy for solid tumours.

Langer CJ.

Expert Opin Investig Drugs. 2004 Nov;13(11):1501-8. Review.

PMID:
15500397
11.

Patient care issues: the management of paclitaxel-related toxicities.

Finley RS, Rowinsky EK.

Ann Pharmacother. 1994 May;28(5 Suppl):S27-30. Review.

PMID:
7915156
12.

Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.

Stinchcombe TE.

Nanomedicine (Lond). 2007 Aug;2(4):415-23. Review.

PMID:
17716129
13.

nab-Paclitaxel dose and schedule in breast cancer.

Martín M.

Breast Cancer Res. 2015 Jun 12;17:81. doi: 10.1186/s13058-015-0587-y. Review.

14.

Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer.

Pinder MC, Ibrahim NK.

Drugs Today (Barc). 2006 Sep;42(9):599-604. Review.

PMID:
17028669
15.

nab-Paclitaxel mechanisms of action and delivery.

Yardley DA.

J Control Release. 2013 Sep 28;170(3):365-72. doi: 10.1016/j.jconrel.2013.05.041. Epub 2013 Jun 11. Review.

PMID:
23770008
16.

[Research progresses of albumin-bound paclitaxel in the treatment of non-small cell lung cancer].

Li P, Wang Q, Wang H, Ma Z.

Zhongguo Fei Ai Za Zhi. 2010 Jul;13(7):748-52. doi: 10.3779/j.issn.1009-3419.2010.07.16. Review. Chinese. No abstract available.

17.

ABI 007.

[No authors listed]

Drugs R D. 2003;4(5):303-5. Review.

PMID:
12952499
18.

Update on nanoparticle albumin-bound paclitaxel.

Socinski M.

Clin Adv Hematol Oncol. 2006 Oct;4(10):745-6. Review. No abstract available.

PMID:
17099631
19.

Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.

Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z.

Recent Pat Anticancer Drug Discov. 2009 Nov;4(3):262-72. Review.

PMID:
19538176
20.

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.

Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Review.

PMID:
24071503
Items per page

Supplemental Content

Write to the Help Desk